Status reference — not a product page. Cora Health does not sell peptides.
Emideltide (DSIP): is it legal in 2026?
No — and it is not an FDA-approved drug.
Emideltide is not on the FDA's Section 503A bulks list, so it is not legal to compound today, and no rulemaking that could change that has been completed. On July 24, 2026, the FDA’s Pharmacy Compounding Advisory Committee voted against adding it to that list — and a committee rejection is not an FDA final decision either. Cora Health does not sell, prescribe, or compound peptides.
PCAC status
Rejected by PCAC — voted against inclusion on the 503A bulks list, 6-7-1, 2026-07-24 (the committee's only rejection)
Legal to compound today
No — not on the FDA 503A bulks list; no final rule
FDA-approved drug
No
Description and FDA-evaluated use
Delta sleep-inducing peptide (DSIP); the uses FDA evaluated were opioid withdrawal, chronic insomnia, and narcolepsy
Human clinical data
None found — FDA cited a lack of safety and efficacy data and inadequate characterization; a witness noted the last study was roughly 30 years old
WADA status
Not addressed in the sources reviewed
Last verified 2026-07-25 · Status Index v1.4.3 · CC-BY-4.0
Where Emideltide actually stands
Emideltide, also called delta sleep-inducing peptide (DSIP), is the one peptide of the seven that the FDA's Pharmacy Compounding Advisory Committee voted AGAINST in July 2026. The uses the FDA evaluated were opioid withdrawal, chronic insomnia, and narcolepsy. No human clinical data was located in the sources reviewed; FDA cited a lack of safety and efficacy data, inadequate characterization of the substance, and existing approved therapies for the proposed uses, and a witness noted the last study was roughly 30 years old. On July 24, 2026 the committee voted 6-7-1 against adding it to the Section 503A bulks list.
How Emideltide got here, and what comes next
Emideltide was not recommended. The pending step below is the FDA's decision on the six peptides that were — Emideltide is not among them, and it is not legal to compound today either way.
-
June 30, 2026
FDA staff review reported — recommends against listing all seven
As reported on June 30, 2026, FDA career scientists highlighted safety risks and what they described as little evidence of benefit, and recommended against adding any of the seven peptides to the 503A bulks list.
-
July 24, 2026
PCAC day two — three peptides evaluated, one rejected
The committee recommended Semax (8-5) and Epitalon (7-5-1), and voted against Emideltide, also called DSIP (6-7-1) — the meeting's only rejection, and its only vote that agreed with FDA staff. Six of seven recommended across the two days.
-
Next step — no date
An FDA decision on the recommendations
The FDA has not acted on the committee's recommendations. Adding any substance to the 503A bulks list requires a full rulemaking — a proposed rule, a public comment period, and a final rule the agency can decline to issue. Rulemaking of this kind has historically run on the order of 12 to 24 months; that duration is our characterization of past FDA rulemakings, not a figure the FDA has published for this one. We are not attaching a date to this, and no one credibly can. This entry updates when the FDA moves.
Emideltide, question by question
Is Emideltide FDA-approved?
No. Emideltide is not an FDA-approved drug. It has not been through the FDA drug-approval process, so the FDA has not established that it is safe or effective, and the July 2026 advisory committee vote did not change that — the committee voted against recommending it, and an advisory vote in either direction is not an FDA decision.
Is Emideltide legal to compound in 2026?
No. Not on the FDA 503A bulks list; no final rule. Adding a substance to the Section 503A bulks list requires a full FDA rulemaking — a proposed rule, a public comment period, and a final rule the agency can decline to issue — and that has not happened for Emideltide. Anyone offering it as legal to order today is describing something that has not occurred.
What did the FDA advisory committee decide about Emideltide?
Rejected by PCAC — voted against inclusion on the 503A bulks list, 6-7-1, 2026-07-24 (the committee's only rejection). PCAC voted against adding Emideltide to the 503A bulks list, aligning with FDA staff, who cited a lack of safety and efficacy data, inadequate characterization, and existing FDA-approved therapies for the proposed uses. Not an FDA final decision either way.
What human clinical evidence exists for Emideltide?
None found — FDA cited a lack of safety and efficacy data and inadequate characterization; a witness noted the last study was roughly 30 years old. Delta sleep-inducing peptide (DSIP); the uses FDA evaluated were opioid withdrawal, chronic insomnia, and narcolepsy. The evidence base for these peptides is thinner than for the compounded GLP-1 medications that licensed providers at Wasef Health, PC prescribe, and nothing here is a claim that Emideltide works. Compounded medications are not FDA-approved.
Does Cora Health sell Emideltide?
No. Cora Health does not sell, prescribe, or compound peptides. Cora does not prescribe medication at all — licensed providers at Wasef Health, PC make every prescribing decision, and the compounded medications Cora does offer are prepared by Hallandale Pharmacy or VialsRx, both US-licensed 503A compounding pharmacies. Compounded medications are not FDA-approved.
Every fact on this page traces to the sources below. Where a fact could not be located in them, the field says so rather than asserting one. See an error? Email help@trycora.io — corrections ship with a dataset version bump.
- FDA — Pharmacy Compounding Advisory Committee (PCAC) — https://www.fda.gov/advisory-committees/human-drug-advisory-committees/pharmacy-compounding-advisory-committee (fetched 2026-07-25)
- FDA — Bulk Drug Substances Nominated for Use in Compounding Under Section 503A — https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-nominated-use-compounding-under-section-503a-fdca (fetched 2026-07-25)
- FDA — July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee (agenda and uses evaluated) — https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026 (fetched 2026-07-25)
- Reuters — FDA staff highlights peptide risks, says little evidence of benefits, 2026-06-30 — https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-staff-highlights-peptide-risks-says-little-evidence-benefits-2026-06-30/ (fetched 2026-06-30)
- RAPS — FDA advisory committee backs two more peptides, rejects one for compounding list, 2026-07-24 — https://www.raps.org/resource/fda-advisory-committee-backs-two-more-peptides-rejects-one-for-compounding-list.html (fetched 2026-07-25)
Not FDA-approved, and not legal to compound today. Emideltide is not an FDA-approved drug and is not on the FDA's Section 503A bulks list. A PCAC recommendation is non-binding advice the FDA can decline, and a PCAC rejection is not an FDA final decision either. Nothing on this page is a claim that Emideltide is safe or effective.
Cora Health does not sell, prescribe, or compound peptides. Cora Health is a telehealth platform that connects patients with licensed independent providers at Wasef Health, PC, who make all prescribing decisions. The compounded medications Cora offers — compounded semaglutide and compounded tirzepatide — are prepared by Hallandale Pharmacy (a PCAB-accredited 503A compounding pharmacy) or VialsRx (a US-licensed 503A compounding pharmacy). Compounded medications are not FDA-approved and are not therapeutically equivalent to FDA-approved branded products. Individual results vary.
General information, not medical or legal advice. If a compliant pathway ever opens, we will say so plainly. Get honest updates →